National
Push for LGBT bills continues during recess
Activities planned in local districts while Congress takes break
Advocacy groups are planning to take advantage of this month’s congressional recess by stepping up efforts with district offices to build support for pro-LGBT initiatives while lawmakers are at home.
One joint effort between the Human Rights Campaign and Servicemembers Legal Defense Network, for example, is geared toward influencing senators to support repealing “Don’t Ask, Don’t Tell” when the issue comes before the Senate, possibly in September.
As part of this same effort, HRC is also working on building support for bringing the Employment Non-Discrimination Act to a House vote.
Meanwhile, grassroots LGBT group GetEqual is considering ways to expand its direct action work outside the Capital Beltway to reach lawmakers in their home districts.
HRC and SLDN last week announced their effort, called Countdown 2010, which aims to mobilize new grassroots efforts to build support in part toward ending “Don’t Ask, Don’t Tell” in the Senate.
Marty Rouse, HRC’s national field director, said the effort consists of engagement from the organization’s field team as well as encouraging HRC members to reach out to key lawmakers.
“We can’t just talk to our legislators and members of Congress inside the Beltway,” Rouse said. “We have to talk to them in the district so that they see that there’s interest and concern back home.”
Aubrey Sarvis, SLDN’s executive director, said the effort will last until lawmakers return from their August recess and vote on the fiscal year 2011 defense authorization bill, the legislative vehicle to which the Senate Armed Services Committee in May attached a provision that would lead to “Don’t Ask, Don’t Tell” repeal.
“We’ll be down in the targeted states with veterans, former clients of SLDN, friends and family of veterans — hopefully to visit with senators and their key staffers to urge senators to support, one, the [Defense Department] bill and, secondly, to support the provisions in the bill as it came out of the Senate Armed Services Committee,” Sarvis said.
The “Don’t Ask, Don’t Tell” portion of the Countdown 2010 effort is focused on influencing senators in 10 states — Arkansas, Indiana, Montana, Nebraska, Nevada, New Hampshire, North Dakota, Ohio, South Dakota and Virginia — where HRC and SLDN feel they don’t have a firm commitment from senators on the issue.
Rouse said the senators in the states on which HRC is focusing its efforts are Blanche Lincoln (D-Ark.), Mark Pryor (D-Ark.), Richard Lugar (R-Ind.), Jon Tester (D-Mont.), Max Baucus (D-Mont.), Mike Johanns (R-Neb.), John Ensign (R-Nev.), Judd Gregg (R-N.H.), Byron Dorgan (D-N.D.), Kent Conrad (D-N.D.), George Voinovich (R-Ohio), Tim Johnson (D-S.D.) and Mark Warner (D-Va.).
Although Rouse said HRC’s field team is engaged in nearly all of these states throughout the country as part of this effort, he added efforts aren’t yet underway in Montana because of priority and efficiency reasons.
“Montana is a big state, and it’s hard to cover and hard to get to,” Rouse said. “There’s no one in Montana right now, but there will be.”
One of the senators on the list has already publicly indicated his position on “Don’t Ask, Don’t Tell” in the defense authorization bill. Last month, Lugar told the Blade he wouldn’t support removing the “Don’t Ask, Don’t Tell” language from legislation and is unlikely to support a filibuster of the main bill.
Sarvis said SLDN feels Indiana should nonetheless be among the states on which efforts are focused.
“With Sen. Lugar, the commitment is not as firm and unequivocal as we would like, so we hope to engage him back home,” Sarvis said. “But, yes, we are somewhat encouraged by what Sen. Lugar has said to date. But, again, it’s not done until all the votes are cast.”
Also as part of Countdown 2010, HRC is working to influence senators in the targeted states on ENDA while engaging House members in North Carolina, Pennsylvania and Texas to build support for the bill. Rouse said urging senators to support ENDA in these three additional states is less of a priority.
“We really focused on the House and we need to do significant [work] in House districts throughout the country before we even can think of the Senate,” Rouse said. “Our focus right now in the field is making sure that we target these House members. That’s most important.”
Paul Guequierre, an HRC spokesperson, said the efforts in North Carolina, Pennsylvania and Texas are geared toward influencing House Democratic members in these states that aren’t ENDA co-sponsors.
Five of eight House Democrats from North Carolina, five of 12 House Democrats from Pennsylvania and five of 12 House Democrats from Texas aren’t co-sponsors, Guequierre said.
Sarvis said the shared work between HRC and SLDN in this effort would complement the strength of each organization. He noted that HRC has more field organizers and thus would provide more field workers to the effort while SLDN would bring more service members and veterans.
“Whether it’s working with field organizers in place or SLDN veterans, clients, it’ll be a matter of sharing resources and bringing that [all] together over the next six to eight weeks in the most efficient way possible,” Sarvis said.
Rouse said HRC would look at local media to determine whether efforts in these states are making progress and noted that efforts in many states have already produced results.
“We’ve already seen letters to the editor printed, op-eds printed and meetings with the Senate staff have already taken place,” he said. “None of this would have happened were it not for HRC’s staff being on the ground, mobilizing and reaching out to people.”
But for SLDN, evaluating the progress of Countdown 2010 would depend on the results of the meetings with senators and their staffers in these states.
“But the bottom line is you won’t know until the votes have been cast,” Sarvis said. “In some cases, we may get affirmative answers over the next several weeks, but I suspect that in many cases, we won’t get a definitive answer until the senators’ votes.”
GetEqual plans district actions
Meanwhile, GetEqual is planning efforts to draw more attention to ENDA as lawmakers return from break. The efforts are intended to build off previous protests last month in Las Vegas and at the U.S. Capitol.
Robin McGehee, co-founder of GetEqual, said her group has been talking with local organizers about working collaboratively on direct action throughout the country on ENDA and “Don’t Ask, Don’t Tell.”
“We’re trying to work to set up some in-district actions,” she said. “At this moment, we don’t have any targets that we’ll release only because we’re trying to figure out where is the weakest link and what we feel like is going to be strategically the best one to plan most of our attention.”
McGehee said GetEqual will be sending out instructions on ways people can engage in the political process as lawmakers work in their home district.
“It may be some people planning actions; it may be just giving them avenues of engagement that can just get them to engage their legislator around ‘Don’t Ask, Don’t Tell’ or ENDA,” she said.
McGehee said GetEqual is looking at lawmakers’ speaking engagements, town halls, fundraisers and office times as possible opportunities for action.
Wherever the actions take place, McGehee said GetEqual is in part learning from the tactics that conservative protesters used in interrupting town hall meetings last year over health care reform.
“Obviously, you don’t want to be compared to someone who has a conservative platform,” she said. “But, in my opinion, one of the things that we did learn from watching that was the squeaky wheel was getting the grease.”
In the past month, GetEqual asked supporters which of four lawmakers should be targeted for direct action over ENDA: U.S. House Speaker Nancy Pelosi (D-Calif.), Senate Majority Leader Harry Reid (D-Nev.), Rep. Barney Frank (D-Mass.) or Rep. George Miller (D-Calif.).
According to GetEqual, Pelosi won 46.5 percent of the vote, Reid won 18.5 percent, Miller took 17.6 percent and Frank took 17.4 percent. The organization declined to make public the total number of votes.
McGehee said the first and second place rankings of Pelosi and Reid were behind a protest last month in Las Vegas, which was directed against Reid, and another protest in the U.S. Capitol, which targeted Pelosi.
But whether GetEqual continues to target Pelosi and Reid during their August break remains to be seen.
“I don’t know for sure that we’ll go back to those targets,” McGehee said. “Honestly, for us, it’s just looking at where you have local organizers that also want to be involved, and finding out from the advocacy groups that really have the inside strategy where do they feel like the hold up is actually happening.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
